BioSpace News Archive

Celgene announced topline data from its Phase III QUAZAR AML-001 trial.

Auris Medical Holding Ltd. announced that it has obtained advice on the development plan and regulatory pathway for its investigational tinnitus treatment Keyzilen® from the U.S. Food and Drug Administration and from the European Medicines Agency.

Horizon Discovery Group plc announces its results for the six months ended 30 June 2019.

A study carried out with a new human stem cell-derived model reveals that the most prevalent genetic risk factor of Alzheimer’s disease, apolipoprotein E4, impairs the function of human brain immune cells, microglia.

Key Opinion Leaders in the field of Proton Therapy shared their latest insights and research on FLASH1 irradiation during IBA’s 3rd Victoria Consortium Meeting and IBA’s symposium on Proton Therapy

BioCardia announced that the independent Data Safety Monitoring Board has completed its prespecified data review for the Phase III pivotal CardiAMP Heart Failure Trial, which included safety follow-up results on 35 patients and all additional data available on the 50 patients randomized in the trial as of August 31, 2019.

Days after reaching a tentative agreement with a majority of states involved in litigation against the company over its role in the opioid crisis in the United States, Purdue Pharmaceuticals filed Chapter 11 bankruptcy.

Brisbane-based world leaders in metagenomic testing, Microba, are among 56 finalists competing for a Lord Mayor’s Award in October this year, as a finalist in the product innovation category.

Mologic Ltd announced that it has finished recruitment to a major clinical trial with University College London Hospitals (UCLH) to evaluate the Company’s point-of-care (POC) diagnostic test for the early detection of sepsis.

Law firm urges Zantac users to find out their rights against drug maker who knowingly sold potentially carcinogenic medication